Conning Jerry Pharmaceuticals: Independently Developed ADC Drug JSKN027 Completes First Patient Dosing

LightningPacketLoss · 2026-03-17T04:23:15+00:00

Generon Coinnovation Pharmaceuticals announced that JSKN027, a bispecific antibody conjugate drug developed by the company, has completed dosing of the first patient in a Phase I clinical study for advanced malignant solid tumors. The drug simultaneously targets PD-L1 and VEGFR2, demonstrating favorable safety and anti-tumor activity.

LightningPacketLoss

2026-03-17 04:23:15

Abstract generation in progress

Recently, Corning Jereh Pharmaceutical announced that the Phase I clinical study of its self-developed bispecific antibody-drug conjugate (ADC) JSKN027, targeting programmed death ligand 1 (PD-L1) and vascular endothelial growth factor receptor 2 (VEGFR2) for the treatment of advanced malignant solid tumors, has completed the first patient dosing.

JSKN027 is a pioneering bispecific antibody ADC that simultaneously targets PD-L1 and VEGFR2. It uses glycoengineering site-specific conjugation technology to precisely attach cleavable linkers and topoisomerase I inhibitors to the Fc region of the antibody, achieving effective anti-tumor activity while maintaining good safety.

(Corning Jereh Pharmaceutical Announcement)

(Editor: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.